GYRE

ANALYST NOTE: GYRE THERAPEUTICS, INC. (GYRE) DATE: 2026-06-13 CURRENT PRICE: $7.00

1. Structural Readiness

• State: Context-only.
• Conservative Entry: —
• Extension: —
• ATR at Breakout: —
• ATR Current: 8.7% (Extreme).
• Pivot Strength: —
• Cap Bucket: Micro.
• Sector: Healthcare.
• Industry: —

Setup Classification: INVALIDATED / NO SETUP.

2. The Thesis Layer

This is a TACTICAL, setup-led name. There is NO named macro or secular thesis attached to this specific setup at this date. The StoryStocks framework requires a named thesis (e.g., "Biotech Re-rating," "China Healthcare Reform") to weight conviction. In the absence of a named thesis, the investment case must be judged strictly on the quality of the technical setup (which is currently absent) and the fundamental business fundamentals. No thesis has been invented for this analysis; the name is being evaluated solely on its operational status and price structure as of 2026-06-13.

3. The Business

Company Overview: Gyre Therapeutics, Inc. is a pharmaceutical company dedicated to discovering, advancing, and commercializing small-molecule drugs targeting inflammation and fibrosis in various organs. The company is based in San Diego, California, and operates as a subsidiary of GNI USA, Inc. (Source: E18, E19).

Business Model & Commercial Status: As of 2026-06-13, Gyre has transitioned from a pure clinical-stage biotech to a commercial-stage biotechnology company with a proven track record in the PRC market. The company generates revenue through the sale of approved small-molecule anti-inflammatory and anti-fibrotic drugs.

Key Commercial Evidence (as of 2026-06-13):

• ETUARY®: Generated annual sales of $106.1 million in 2025. This is the company's primary revenue driver (Source: E14).
• Etorel®: Launched in the PRC in June 2025. Following selection in the National Centralized Drug Procurement (NCDP) in November 2025, implementation commenced in March 2026. Etorel generated $4.6 million in sales in 2025 (Source: E7, E8, E15).
• Contiva® (Avatrombopag): Launched in the PRC in March 2025, generating $5.5 million in sales in 2025 (Source: E16).
• Market Context: The company focuses on organ fibrosis. The prevalence of Idiopathic Pulmonary Fibrosis (IPF) in the PRC is growing at a CAGR of 10.24% (2018–2024) and is projected to reach 332,000 patients by 2032 (Source: E17).

Pipeline & Management Expectations:

• Hydronidone (F351): In May 2025, the pivotal Phase 3 trial met its primary endpoint (52.85% vs 29.84% fibrosis regression). Management expects to submit an NDA seeking conditional approval in the first half of 2026 (Source: E10, E11).
• U.S. Expansion: Pending regulatory feedback, management intends to file a U.S. IND in 2026 and, if effective, initiate a Phase 2 clinical trial (Source: E12).
• RILI: The NMPA approved the trial application in March 2025. Management expects to initiate an adaptive Phase 2/3 study in the first half of 2026 (Source: E13).
• Historical Context (2021): Earlier plans to submit an IND for 4332 in 2022 and initiate trials were recorded, though the 2021 transcript noted a financing hurdle for the MAA-304 study without a partner (Source: E1, E2).

4. Archetype and Conviction

Archetype: Margin Inflector / Commercial-Stage Recovery. The company fits the archetype of a commercial-stage biotech that has successfully monetized a core asset (ETUARY) and is now leveraging that cash flow to fund the commercialization of new assets (Etorel, Contiva) and the regulatory submission of its next-generation candidate (Hydronidone). The business model has shifted from "burning cash for trials" to "generating revenue from NCDP contracts."

Valuation & Financial Spine:

• Forward Consensus EPS (FY1): -0.29.
• Forward Consensus EPS (FY2): -0.10.
• Coverage: Financial spine coverage is "complete" (Source: E21).
• Analysis: The company is still reporting negative earnings, but the trajectory shows a narrowing of losses (-0.29 to -0.10), consistent with the ramp-up of commercial sales ($106M + $4.6M + $5.5M in 2025). The "Micro" cap bucket suggests high volatility and liquidity constraints.

Conviction Stack:

• Thesis Strength: Low (No named secular thesis).
• Evidence Quality: High (Strong commercial data, clear regulatory milestones, specific sales figures).
• Structural Quality: None. The setup is not formed.
• Rerating Potential: High *if* the structural setup forms, but currently unactionable. The "Extreme" ATR (8.7%) indicates the stock is currently in a high-volatility state, which is a negative signal for a "forming" setup and a severe risk for a "confirmed" setup without a defined entry.

Conclusion on Conviction:

5. Invalidations, Strengths, and Gaps

What Would Invalidate the Case:

• Fundamental: Failure to submit the Hydronidone NDA in H1 2026 as expected by management.
• Regulatory: Rejection of the NDA or failure to secure NCDP contracts for Etorel beyond the initial implementation.

What Would Strengthen the Case:

• Fundamental: Confirmation of the Hydronidone NDA submission and positive feedback from the FDA/NMPA.
• Commercial: Acceleration of Etorel sales beyond the $4.6M 2025 run-rate, driven by the NCDP implementation.

Gaps in Evidence:

• Missing Evidence: No specific data on the *current* cash balance or burn rate as of Q1/Q2 2026, only the 2021 cash position ($64.5M) and 2025 sales figures.
• Missing Evidence: No specific details on the *current* U.S. IND status or the exact timing of the Phase 2 initiation beyond management's "expectation."

PRIVATE ANALYST CALL

Judgment: Speculative Confidence: low Key evidence: ETUARY generated $106.1M in 2025; Hydronidone Phase 3 met primary endpoint; Management expects NDA submission in H1 2026. Expected path: Management expects NDA submission and potential U.S. IND filing in 2026; commercial sales of Etorel and Contiva should continue to ramp. Expected horizon: 12 to 24 months for regulatory milestones and commercial ramp. Failure mode to watch: Failure to submit Hydronidone NDA in H1 2026 or a structural breakdown in price that invalidates any future setup formation.